What is Artelo Biosciences Price-to-Free-Cash-Flow?
As of today (2024-06-05), Artelo Biosciences's share price is $0.0131.
Artelo Biosciences's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00. Hence, Artelo Biosciences's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for Artelo Biosciences's Price-to-Free-Cash-Flow or its related term are showing as below:
ARTLW's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.345 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 46.00% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 40.10% per year.
During the past 10 years, Artelo Biosciences's highest 3-Year average Free Cash Flow per Share Growth Rate was 54.30% per year. The lowest was -372.30% per year. And the median was -72.70% per year.
Artelo Biosciences Price-to-Free-Cash-Flow Historical Data
The historical data trend for Artelo Biosciences's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Artelo Biosciences's Price-to-Free-Cash-Flow
For the Biotechnology subindustry, Artelo Biosciences's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Artelo Biosciences's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Artelo Biosciences's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Artelo Biosciences's Price-to-Free-Cash-Flow falls into.
Artelo Biosciences's Share Price of today is $0.0131. Artelo Biosciences's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Artelo Biosciences Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Artelo Biosciences's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Artelo Biosciences (Artelo Biosciences) Business Description
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing and commercializing treatments that control endocannabinoid system. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ARTLW has been successfully added to your 